Global Supply Chain Disruptions Worsen US ADHD Drug Shortage

A new report from CIDRAP connects ongoing ADHD drug shortages in the United States directly to broader global supply chain disruptions, signaling that pharmaceutical supply issues extend beyond isolated incidents to systemic vulnerabilities. The shortage reflects stress points in the international movement of active pharmaceutical ingredients (APIs), manufacturing capacity constraints, and logistics bottlenecks that have persisted despite broader economic recovery. For supply chain professionals in healthcare and pharma, this underscores the critical need for visibility into multi-tier supplier networks and the risks of geographic concentration in API sourcing.

The ADHD medication shortage represents a high-impact, slow-burn crisis that affects millions of American patients and creates downstream pressure on healthcare providers and pharmaceutical companies. Unlike acute supply chain events, this shortage has developed over months, indicating structural challenges rather than temporary disruptions. The global nature of the problem—involving cross-border ingredient flows, manufacturing dependencies, and logistics coordination—demonstrates how vulnerabilities in one region propagate through interconnected supply networks.

Pharmaceutical supply chain leaders must reassess their dual-sourcing strategies, geographic diversification of suppliers, and inventory buffer policies. The incident highlights the importance of supply chain scenario planning, real-time demand forecasting, and proactive engagement with regulatory bodies to manage shortages before they reach critical stages.